インタラクティブディスカッション

研究の進展や動向、いま直面している課題について、業界のエキスパートや同業他社と共に徹底的に討論することができます。

インタラクティブディスカッション・グループでは、将来の協力相手とのネットワーク作りに不可欠な役割を果たします。このグループは、研究成果をシェアし、仲間とアイデアを出し合い、グループで問題解決に取り組む機会が提供されます。

インタラクティブディスカッションは対面形式でのみ実施されます。

8月20日 火曜日

INTERACTIVE DISCUSSIONS: IN-PERSON ONLY

7:30 am Interactive Discussions with Continental Breakfast
Interactive discussions provide an opportunity to discuss a focused topic with peers from around the world in an open, collegial setting. Select from the list of topics available and join the moderated discussion to share ideas, gain insights, establish collaborations or commiserate about persistent challenges.

How to Successfully Partner with DDDI and BARDA
Christopher J. Knickerbocker, Contracting Officer Representative, United States Department of Health and Human Services
Kristy Stoudt, PhD, Biologist and Project Officer, Biomedical Advanced Research and Development Authority (BARDA)

• Preliminary inquiries and interactions
• Funding mechanisms
• BAA solicitation process (Stage I - III)
• Key questions before starting a submission/advice for submitters

Funding and Commercialization Resources for Cancer Technologies
Linda K. Zane, PhD, Program Director, SBIR Development Center, National Cancer Institute

• NIH-wide SBIR and STTR
• Funding opportunities
• Application tips
• Assistance and initiatives for awardees and applicants

Sponsored Testing: Ensuring Patients Have Compliant Access to a Timely Accurate Diagnosis
Nicole Miller, PhD, Vice President, Molecular Diagnostics, Ultragenyx Pharmaceutical, Inc.
Vanessa Rangel Miller, Senior Director, Molecular Diagnostics, Ultragenyx Pharmaceutical, Inc.

• How and why does sponsored testing aid timely diagnosis for patients?
• What are key elements of a compliant sponsored testing program?
• What can we learn from sponsored testing programs to aid timely, accurate patient diagnosis?

8月21日 水曜日

INTERACTIVE DISCUSSIONS: IN-PERSON ONLY

7:30 am Interactive Discussions with Continental Breakfast
Interactive discussions provide an opportunity to discuss a focused topic with peers from around the world in an open, collegial setting. Select from the list of topics available and join the moderated discussion to share ideas, gain insights, establish collaborations or commiserate about persistent challenges.

How to Successfully Partner with DDDI and BARDA
Christopher J. Knickerbocker, Contracting Officer Representative, United States Department of Health and Human Services
Kristy Stoudt, PhD, Biologist and Project Officer, Biomedical Advanced Research and Development Authority (BARDA)

• Preliminary inquiries and interactions
• Funding mechanisms
• BAA solicitation process (Stage I - III)
• Key questions before starting a submission/advice for submitters

Sponsored Testing: Ensuring Patients Have Compliant Access to a Timely Accurate Diagnosis
Nicole Miller, PhD, Vice President, Molecular Diagnostics, Ultragenyx Pharmaceutical, Inc.
Vanessa Rangel Miller, Senior Director, Molecular Diagnostics, Ultragenyx Pharmaceutical, Inc.

• How and why does sponsored testing aid timely diagnosis for patients?
• What are key elements of a compliant sponsored testing program?
• What can we learn from sponsored testing programs to aid timely, accurate patient diagnosis?

Value Creation to Enhance Market Access Success
Lauren Feldman, Vice President and Head, Value, Access, and Pricing, ADVI

• Value creation tools/processes
• Considerations for a compelling value proposition
• Considerations for maximizing value

Incorporating Risk into Early Cancer Screening
Megan P. Hall, PhD, Vice President, Medical Affairs, GRAIL LLC
Sam Hanash, MD, PhD, Director, Red & Charline McCombs Institute; Evelyn & Sol Rubenstein Distinguished Chair, Cancer Prevention; Professor, Clinical Cancer Prevention-Research, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
How and to what extent should evaluations of cancer risk be a factor in early cancer screening guidelines? What are the pros and cons of enriching clinical trials with patients more likely to develop cancer? How might cancer risk have an impact on algorithm learning?